Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Guest

Showing results (201-210 of 492) with videos related to

Pageof 50
Sort By:
Journal of Neurotrauma|July 18, 2013
A prospective, multicenter, phase I matched-comparison group trial of safety, pharmacokinetics, and preliminary efficacy of riluzole in patients with traumatic spinal cord injuryRobert G Grossman, Michael G Fehlings, Ralph F Frankowski, et al.
Journal of Neurosurgery. Spine|September 19, 2012
Incidence and severity of acute complications after spinal cord injuryRobert G Grossman, Ralph F Frankowski, Keith D Burau, et al.
Plos Pathogens|May 18, 2019
Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine designZhen-Yong Keck, Brian G Pierce, Patrick Lau, et al.
Journal of Neurotrauma|April 4, 2023
Interhospital Transfer Delays Care for Spinal Cord Injury Patients: A Report from the North American Clinical Trials Network for Spinal Cord InjuryMargot Kelly-Hedrick, Beatrice Ugiliweneza, Elizabeth G Toups, et al.
Journal of Clinical Pharmacology|April 28, 2021
Longitudinal Impact of Acute Spinal Cord Injury on Clinical Pharmacokinetics of Riluzole, a Potential Neuroprotective AgentAshley Nguyen, Diana S-L Chow, Lei Wu, et al.
Journal of Neurotrauma|March 8, 2023
Bulbocavernosus Reflex Has No Prognostic Features During the Acute Evaluation of Spinal Cord InjuriesDaniyal Mansoor Ali, Ahilan Sivaganesan, Chris J Neal, et al.
Global Spine Journal|February 17, 2022
Developing Peri-Operative Rehabilitation in Degenerative Cervical Myelopathy [AO Spine RECODE-DCM Research Priority Number 6]: An Unexplored Opportunity?Timothy F Boerger, Allison S Hyngstrom, Julio C Furlan, et al.
Cancer Immunology, Immunotherapy : CII|June 30, 2017
The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicityFiona C Thistlethwaite, David E Gilham, Ryan D Guest, et al.
Global Spine Journal|February 17, 2022
Optimizing the Application of Surgery for Degenerative Cervical Myelopathy [AO Spine RECODE-DCM Research Priority Number 10]Ricardo Rodrigues-Pinto, Thiago S Montenegro, Benjamin M Davies, et al.
Spinal Cord|December 21, 2006
Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP Panel: clinical trial inclusion/exclusion criteria and ethicsM H Tuszynski, J D Steeves, J W Fawcett, et al.
Pageof 50

Showing results (201-210 of 492) with videos related to

Sort By:
Pageof 50
Journal of Neurotrauma|July 18, 2013
A prospective, multicenter, phase I matched-comparison group trial of safety, pharmacokinetics, and preliminary efficacy of riluzole in patients with traumatic spinal cord injuryRobert G Grossman, Michael G Fehlings, Ralph F Frankowski, et al.
Journal of Neurosurgery. Spine|September 19, 2012
Incidence and severity of acute complications after spinal cord injuryRobert G Grossman, Ralph F Frankowski, Keith D Burau, et al.
Plos Pathogens|May 18, 2019
Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine designZhen-Yong Keck, Brian G Pierce, Patrick Lau, et al.
Journal of Neurotrauma|April 4, 2023
Interhospital Transfer Delays Care for Spinal Cord Injury Patients: A Report from the North American Clinical Trials Network for Spinal Cord InjuryMargot Kelly-Hedrick, Beatrice Ugiliweneza, Elizabeth G Toups, et al.
Journal of Clinical Pharmacology|April 28, 2021
Longitudinal Impact of Acute Spinal Cord Injury on Clinical Pharmacokinetics of Riluzole, a Potential Neuroprotective AgentAshley Nguyen, Diana S-L Chow, Lei Wu, et al.
Journal of Neurotrauma|March 8, 2023
Bulbocavernosus Reflex Has No Prognostic Features During the Acute Evaluation of Spinal Cord InjuriesDaniyal Mansoor Ali, Ahilan Sivaganesan, Chris J Neal, et al.
Global Spine Journal|February 17, 2022
Developing Peri-Operative Rehabilitation in Degenerative Cervical Myelopathy [AO Spine RECODE-DCM Research Priority Number 6]: An Unexplored Opportunity?Timothy F Boerger, Allison S Hyngstrom, Julio C Furlan, et al.
Cancer Immunology, Immunotherapy : CII|June 30, 2017
The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicityFiona C Thistlethwaite, David E Gilham, Ryan D Guest, et al.
Global Spine Journal|February 17, 2022
Optimizing the Application of Surgery for Degenerative Cervical Myelopathy [AO Spine RECODE-DCM Research Priority Number 10]Ricardo Rodrigues-Pinto, Thiago S Montenegro, Benjamin M Davies, et al.
Spinal Cord|December 21, 2006
Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP Panel: clinical trial inclusion/exclusion criteria and ethicsM H Tuszynski, J D Steeves, J W Fawcett, et al.
Pageof 50